References
- Considerations for physicians on switching decisions regarding biosimilars. European Biopharmaceutical Enterprises; European Federation of Pharmaceutical Industries and Associations; International Federation of Pharmaceutical Manufacturers and Associations [cited 2018 Apr 3]. https://www.ebe-biopharma.eu/wpcontent/uploads/2017/04/considerations-forswitching-decisions_biosimilars-and-rbps-finalbranded-1.pdf.
- Brodszky V, Baji P, Balogh O, et al. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in sex Central and Eastern European countries. Eur J Health Econ. 2014;15:65–71.
- Jha A, Upton A, Dunlop W, et al. The budget impact of biosimilar infliximab (Remsima) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32:742–756.
- Araújo FC, Gonçalves J, Fonseca JE. Pharmacoeconomics of biosimilars: what is there to gain from them? Curr Rheumatol Rep. 2016;18:50.
- Ruff L, Rezk MF, Uhlig T, et al. Budget impact analysis of an etanercept biosimilar for the treatment of rheumatoid arthritis in Europe. Value Health. 2015;18:A639.
- Aladul MI, Fitzpatrick RW, Chapman SR. Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK. BioDrugs. 2017;31:533–544.
- Wu B, Song Y, Leng L, et al. Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars. Clin Exp Rheumatol. 2015;33:20–26.
- Abdalla A, Byrne N, Conway R, et al. Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product. OARRR. 2017;9:29–35.
- Yazici Y, Xie L, Ogbomo A, et al. Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product. Biologics. 2018;12:127–134.
- Cantini F, Benucci M. Focus on biosimilar etanercept – bioequivalence and interchangeability. BTT. 2018;12:87–95.
- Cantini F, Benucci M. Additional comment to: ‘Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?’ by Scherlinger and Schaeverbeke. Ann Rheum Dis. 2019;78:e25.
- Gibofsky A, Skup M, Yang M, et al. Short-term costs associated with non-medical switching in autoimmune conditions. Clin Exp Rheumatol. 2019;37:97–105.
- Tarallo M, Onishchenko K, Alexopoulos S. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK. J Med Econ. 2019 Aug 2:1.